Drug
Bosutinib clinical trials
Also written SKI-606 and Bosulif.
- studies test it
- 51
- open now
- 2
- in phase 3
- 2
- first study started
- 2004
Keep track of what changes. Save the bosutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2008 (6)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 30
- Phase 2
- 22
- Phase 3
- 2
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 33 · Other 18
Pfizer (20) · Wyeth is now a wholly owned subsidiary of Pfizer (13) · M.D. Anderson Cancer Center (3) · Children's Oncology Group (1) · Kyoto University (1) · Georgetown University (1) · Medical College of Wisconsin (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1)
Often tested with
Tested in the same studies.
Dasatinib (3) · Imatinib (2) · Nilotinib (2) · Axitinib (2) · Inotuzumab Ozogamicin (1) · Pemetrexed (1) · Dabigatran (1) · Lansoprazole (1)
Studies
Open first, then newest update. How each study uses bosutinib is read from its arms, and is right about nine times in ten.
Testing it · 51
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Bosutinib
- Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative DementiasEnrolling by invitationPhase 1Neurological Associates of West Los AngelesNCT02921477Written as bosutinib
- Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid LeukemiaActive, not recruitingPhase 1/2Children's Oncology GroupNCT04258943Written as Bosutinib
- iPSC-based Drug Repurposing for ALS Medicine (iDReAM) StudyCompletedPhase 1/2Kyoto UniversityNCT04744532Written as Bosutinib (Phase 1 part)
- Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy BodiesCompletedPhase 2Georgetown UniversityNCT03888222Written as Bosutinib Oral Tablet
- Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed ConditionCompletedPhase 1PfizerNCT04916769Written as Bosutinib capsule
- Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib CapsuleCompletedPhase 1PfizerNCT05032690Written as Bosutinib capsule
- Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult PatientsTerminatedPhase 1/2Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaNCT04793399Written as Bosutinib 400 MG Monotherapy
- Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedPhase 1/2M.D. Anderson Cancer CenterNCT02311998Written as Bosutinib
- The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedPhase 2Medical College of WisconsinNCT02269267Written as Bosutinib (Stopping their TKI)
- Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT02810990Written as Bosutinib
- Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008CompletedNot applicablePfizerNCT01903733Written as bosutinib
- Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCompletedPhase 1Nagla Abdel KarimNCT03023319Written as Bosutinib
- Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedPhase 2PfizerNCT03128411Written as Bosutinib
- Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed ConditionCompletedPhase 1PfizerNCT04549480Written as Bosutinib capsule
- Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase InhibitorsTerminatedPhase 4PfizerNCT02228382Written as Bosutinib
- Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast CancerTerminatedPhase 2PfizerNCT00880009Written as Bosutinib
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedPhase 3PfizerNCT02130557Written as Bosutinib
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedPhase 1M.D. Anderson Cancer CenterNCT02782403Written as Bosutinib
- Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyCompletedPhase 2University of Milano BicoccaNCT02638467Written as Bosutinib
See all 51 studies that test bosutinib →
Given in every arm · 4 — bosutinib is usual care beside what is tested
- Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingPhase 3Ascentage Pharma Group Inc.NCT06423911Written as Bosutinib
- Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From DiagnosisCompletedPhase 2St. Olavs HospitalNCT03831776Written as Bosutinib
- WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorCompletedPhase 1Georgetown UniversityNCT03854903Written as Bosutinib
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Bosutinib Monohydrate
As the comparator · 4 — what is tested is compared with bosutinib
- Asciminib Roll-over StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04877522Written as Bosutinib
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04971226Written as Bosutinib
- Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIsCompletedPhase 3Novartis PharmaceuticalsNCT03106779Written as Bosutinib
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingPhase 2SWOG Cancer Research NetworkNCT03654768Written as Bosutinib
Codes
What other systems call bosutinib · ClinicalTrials.gg INT004509
- MeSH (NLM) C471992bosutinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5018V4AEZ0BOSUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1307619Confirmed FDA, Wikidata
- Wikidata Q894611bosutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C60809BosutinibConfirmed FDA, Wikidata
- DrugBank DB06616One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C471992 | bosutinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5018V4AEZ0 | BOSUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1307619 | — | Confirmed FDA, Wikidata |
| Wikidata | Q894611 | bosutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C60809 | Bosutinib | Confirmed FDA, Wikidata |
| DrugBank | DB06616 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.